Anders Gersel Pedersen. Picture: Avillion LLP

Avillion appoints Dr Anders Gersel Pedersen

Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.

Avillion LLP’s CEO, Dr Allison Jeynes commented: “Anders has an impressive track record in developing new medicines demonstrated by his distinguished career in research and development within the pharmaceutical industry. I am delighted that Avillion is now set to benefit from this experience as we continue to deliver on the clinical programmes we are running and to assess new opportunities.”

Dr Pedersen added: “Avillion has demonstrated the successful outcome that its novel co-development and financing model can deliver with the approval and expanded label for Bosulif in chronic myelogenous leukaemia. I am pleased to join the company as it advances further programmes and hope I can make a contribution to expedite the availability of new medicines to help patients.”

Avillion was founded in 2012 and is backed by Abingworth and Blackstone Life Sciences (previously Clarus Ventures).